Tag Archives: treated multiple myeloma

20th EHA Congress in Vienna: Novartis data shows increased PFS benefit of Farydak® in new subgroup of patients with previously treated multiple myeloma

Panobinostat combination more than doubled median PFS benefit by 7.8 months in patients who received >=2 prior lines of therapy, including bortezomib and IMiD[1] Multiple myeloma is an incurable cancer of the plasma cells, a type of white blood cell … Read the full press release